<SEC-DOCUMENT>0001193125-24-195940.txt : 20240807
<SEC-HEADER>0001193125-24-195940.hdr.sgml : 20240807
<ACCEPTANCE-DATETIME>20240807162908
ACCESSION NUMBER:		0001193125-24-195940
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240807
DATE AS OF CHANGE:		20240807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIODESIX INC
		CENTRAL INDEX KEY:			0001439725
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				203986492
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-261095
		FILM NUMBER:		241184258

	BUSINESS ADDRESS:	
		STREET 1:		919 WEST DILLON ROAD
		CITY:			LOUISVILLE
		STATE:			CO
		ZIP:			80027
		BUSINESS PHONE:		303-417-0500

	MAIL ADDRESS:	
		STREET 1:		919 WEST DILLON ROAD
		CITY:			LOUISVILLE
		STATE:			CO
		ZIP:			80027
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d868591d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SUPPLEMENT NO. 2 DATED AUGUST&nbsp;7, 2024 TO</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT DATED DECEMBER&nbsp;22, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>Filed pursuant to Rule 424(b)(5)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>(to Prospectus dated November&nbsp;29, 2021)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-261095</FONT></B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Up to $50,000,000 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g868591g0806072430512.jpg" ALT="LOGO" STYLE="width:2.46319in;height:0.454861in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Supplement No.&nbsp;2
to the Prospectus Supplement (this &#147;Supplement No.&nbsp;2&#148;) supplements and amends the Prospectus Supplement dated December&nbsp;22, 2021, as supplemented and amended by Supplement No.&nbsp;1 dated April&nbsp;5, 2024 (as supplemented and
amended, the &#147;Prospectus Supplement&#148;). This Supplement No.&nbsp;2 should be read in conjunction with the Prospectus Supplement and the Prospectus dated November&nbsp;29, 2021, filed with the Securities and Exchange Commission as a part of
our registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261095)</FONT> (the &#147;Prospectus&#148;). This Supplement No.&nbsp;2 is qualified by reference to the Prospectus
Supplement, except to the extent that the information presented herein supersedes the information contained in the Prospectus Supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
November&nbsp;15, 2021, we entered into a Sales Agreement, dated November&nbsp;15, 2021 (the &#147;Sales Agreement&#148;), with TD Securities (USA) LLC (f/k/a Cowen and Company, LLC) (&#147;TD Cowen&#148;) relating to shares of our common stock
offered by the Prospectus Supplement. In accordance with the terms of the Sales Agreement, we could offer and sell shares of our common stock having an aggregate offering price of up to $50,000,000 from time to time through TD Cowen pursuant to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> transactions (&#147;ATM&#148;). As of the date of this Supplement No.&nbsp;2, we have sold an aggregate of 6,403,703 shares of our common stock pursuant to the
Sales Agreement for aggregate gross proceeds of $21,772,134.37. Consequently, up to approximately $28.2&nbsp;million remains available under the Sales Agreement pursuant to this Prospectus Supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The NASDAQ Global Market under the symbol &#147;BDSX.&#148; The aggregate market value of our common stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> as of August&nbsp;5, 2024 pursuant to General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> is $116,128,229, which was calculated based on 73,967,025 shares of our common stock
outstanding held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> and at a price of $1.57 per share, the closing price of our common stock on August&nbsp;5, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the SEC&#146;s &#147;baby shelf rules,&#148; which prohibit companies with a public float of less than $75&nbsp;million from issuing securities under a
shelf registration statement in excess of <FONT STYLE="white-space:nowrap">one-third</FONT> of such company&#146;s public float in a <FONT STYLE="white-space:nowrap">12-month</FONT> period, on April&nbsp;5, 2024 we supplemented the Prospectus
Supplement to reduce the size of the continuous offering by us under the Prospectus Supplement to up to $100,000 of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are no longer subject to
the SEC&#146;s &#147;baby shelf rules,&#148; and the purpose of this Supplement No.&nbsp;2 is to increase the size of the continuous offering by us under the Prospectus Supplement to up to $50,000,000 of shares, effective on August&nbsp;7, 2024.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation to TD Cowen for sales of common stock sold pursuant to the Sales Agreement will be an amount equal to 3% of the gross proceeds of any
shares of common stock sold under the Sales Agreement. In connection with the sale of the common stock on our behalf, TD Cowen will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of TD Cowen
will be deemed to be underwriting commissions or discounts. See &#147;Plan of Distribution&#148; beginning on page <FONT STYLE="white-space:nowrap">S-20</FONT> of the Prospectus Supplement for additional information regarding the compensation to be
paid to TD Cowen. We have also agreed to provide indemnification and contribution to TD Cowen with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; under federal
securities laws and as such, have elected to comply with reduced public company reporting requirements for this prospectus and the documents incorporated by reference herein and may elect to comply with reduced public company reporting requirements
in future filings. See &#147;Summary&#151;Implications of Being an Emerging Growth Company and Smaller Reporting Company&#148; in the Prospectus Supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our business and an investment in our common stock involve significant risks. These risks are described under the caption &#147;Risk Factors&#148;
beginning on page <FONT STYLE="white-space:nowrap">S-7</FONT> of the Prospectus Supplement and in the documents incorporated by reference into the Prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus and the accompanying prospectus are truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>TD Cowen </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this Supplement No.&nbsp;2 to the Prospectus Supplement is August&nbsp;7, 2024. </B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g868591g0806072430512.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g868591g0806072430512.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  K .D# 2(  A$! Q$!_\0
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:6WM((X($SMCC4*HSSP!4U<KM?0ZE>VI__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
